Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 13.

Figure 13

Absolute benefits and risks of hormone replacement therapy in women 50–59 years of age when randomized in the Women’s Health Initiative trials of conjugated equine estrogen alone (CEE) and continuous combined conjugated equine estrogen plus medroxyprogesterone acetate (CEE+MPA) (31). Absolute benefits and risks expressed as difference between number of events in hormone replacement therapy group and number of events in placebo group per 10,000 women per year. Absolute risk of 10/10,000 is delineated to show relation of number of additional events with the category of rare frequency of events (Table 4). *Deep vein thrombosis is the only statistically significant adverse event.